Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines

Bulletin Express

Yesterday

Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.

These vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1178407621"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178407621\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178407621?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178407621","market":"us","top_or_hot":-1,"title":"Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines","media":"Bulletin Express","content":"<p>Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.</p>\n<p>These vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAb&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-13 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.</p>\n<p>These vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"","article_id":"1178407621","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178407621","pubTimestamp":1763023341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"Ab&B Bio-Tech(2627)宣布开始流感疫苗I期临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":1},"content_text":"Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.\nThese vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}